Global Benign Prostatic Hyperplasia Treatment Market Size,
Share & Trends Analysis Report and Forecast Period 2022-
2028
The global benign prostatic hyperplasia market is estimated to grow at a CAGR of around 7%
during the forecast period. Benign prostatic hyperplasia (BPH), is a condition in which men’s
prostate gland gets enlarged, though not cancerous. Benign prostatic hyperplasia is also named
as benign prostatic hypertrophy or benign prostatic obstruction. Men’s prostate gland gets
enlarged mainly in two stages, first occurs during puberty, and second-growth occurs around
age 25 and continues during most of a man’s life. This BPH mainly occurs during the second-
growth phase. According to the National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), BPH is among the common prostate problem for men, who are older than
age 50, and in 2010 in the US, nearly 14 million men had BHP symptoms. BPH affects nearly
50% of men between the ages of 51-60 and 90% of men age above 80.
Get Free Sample link @ https://www.omrglobal.com/request-sample/benign-
prostatic-hyperplasia-treatment-market
The rising frequency of benign prostatic hyperplasia is the key factor, which is a major driver of
this market growth. Besides, public awareness, the government initiatives, an increase in health
budget are also driving the global benign prostatic hyperplasia market growth. Researchers
found that there is an alarmingly increasing rate of benign prostatic hyperplasia among the
middle-aged and old-aged men. Since people are less aware of the BHP, many country's
governments are launching many awareness campaigns to spread awareness about BPH
symptoms and treatment. For instance, the US health advocate and health authorities conduct
prostate health awareness campaign the “National Prostate Health Month” every year in
September, to educate the people about the risk and treatment, that are associates with benign
prostatic hyperplasia.
A full report of Global Benign Prostatic Hyperplasia Treatment Marke